JP2018532790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532790A5 JP2018532790A5 JP2018541593A JP2018541593A JP2018532790A5 JP 2018532790 A5 JP2018532790 A5 JP 2018532790A5 JP 2018541593 A JP2018541593 A JP 2018541593A JP 2018541593 A JP2018541593 A JP 2018541593A JP 2018532790 A5 JP2018532790 A5 JP 2018532790A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- migraine
- oxo
- bipiperidin
- dihydroquinolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- -1 7-methyl-1H-indazol-5-yl Chemical group 0.000 claims 13
- 206010027599 Migraine Diseases 0.000 claims 8
- 208000008085 Migraine Disorders Diseases 0.000 claims 6
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010047700 Vomiting Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000001314 paroxysmal Effects 0.000 claims 2
- 230000000737 periodic Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 206010049714 Abdominal migraine Diseases 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 206010003791 Aura Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 206010050258 Basilar migraine Diseases 0.000 claims 1
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- LHTDFZHWXGJKAC-JGCGQSQUSA-N CC=1C=C(C=C2C=NNC=12)C[C@H](C(=O)N1CCC(CC1)N1CCC(CC1)C=1NC(=NN=1)C(=O)O)NC(=O)N1CCC(CC1)C=1C(NC2=CC=CC=C2C=1)=O Chemical compound CC=1C=C(C=C2C=NNC=12)C[C@H](C(=O)N1CCC(CC1)N1CCC(CC1)C=1NC(=NN=1)C(=O)O)NC(=O)N1CCC(CC1)C=1C(NC2=CC=CC=C2C=1)=O LHTDFZHWXGJKAC-JGCGQSQUSA-N 0.000 claims 1
- ZBZJVLNNWXGGTH-UUWRZZSWSA-N CC=1C=C(C=C2C=NNC=12)C[C@H](C(=O)N1CCC(CC1)N1CCC(CC1)C=1NC(=NN=1)C(=O)OCC)NC(=O)N1CCC(CC1)C=1C(NC2=CC=CC=C2C=1)=O Chemical compound CC=1C=C(C=C2C=NNC=12)C[C@H](C(=O)N1CCC(CC1)N1CCC(CC1)C=1NC(=NN=1)C(=O)OCC)NC(=O)N1CCC(CC1)C=1C(NC2=CC=CC=C2C=1)=O ZBZJVLNNWXGGTH-UUWRZZSWSA-N 0.000 claims 1
- 206010058019 Cancer pain Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 208000001636 Diabetic Neuropathy Diseases 0.000 claims 1
- 206010012680 Diabetic neuropathy Diseases 0.000 claims 1
- 208000002173 Dizziness Diseases 0.000 claims 1
- 206010014020 Ear pain Diseases 0.000 claims 1
- 206010067039 Familial hemiplegic migraine Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010019233 Headache Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010052784 Retinal migraine Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 208000006122 Sporadic Hemiplegic Migraine Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000004371 Toothache Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000001084 cerebrovascular disease Diseases 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000009273 endometriosis Diseases 0.000 claims 1
- 201000005569 gout Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000000968 intestinal Effects 0.000 claims 1
- 230000002175 menstrual Effects 0.000 claims 1
- 230000002085 persistent Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000011528 vascular disease Diseases 0.000 claims 1
- WFXDPWZNULOEPH-UHFFFAOYSA-N CC(C)c1c(C)nc[nH]1 Chemical compound CC(C)c1c(C)nc[nH]1 WFXDPWZNULOEPH-UHFFFAOYSA-N 0.000 description 2
- QBDXSEYWEKKYSH-UHFFFAOYSA-N Cc1nnc[n]1C Chemical compound Cc1nnc[n]1C QBDXSEYWEKKYSH-UHFFFAOYSA-N 0.000 description 2
- NXBWLJDDASRJRU-VVDKBYALSA-N CC1C(C(CC2)CCN2C(CCC2)CCC2C([C@@H](Cc2cc(C)c3[nH]ncc3c2)NC(C=C(CC2)CCC2C2=Cc(cccc3)c3NCC2=O)=O)=O)=NN=C1 Chemical compound CC1C(C(CC2)CCN2C(CCC2)CCC2C([C@@H](Cc2cc(C)c3[nH]ncc3c2)NC(C=C(CC2)CCC2C2=Cc(cccc3)c3NCC2=O)=O)=O)=NN=C1 NXBWLJDDASRJRU-VVDKBYALSA-N 0.000 description 1
- KLENFGVWYLLZFQ-PGUFJCEWSA-N Cc1c(C(CC2)CCN2C(CC2)CCN2C([C@@H](Cc2cc(C)c3[nH]ncc3c2)NC(N(CC2)CCC2C2=Cc(cccc3)c3NC2=O)=O)=O)[nH]cn1 Chemical compound Cc1c(C(CC2)CCN2C(CC2)CCN2C([C@@H](Cc2cc(C)c3[nH]ncc3c2)NC(N(CC2)CCC2C2=Cc(cccc3)c3NC2=O)=O)=O)[nH]cn1 KLENFGVWYLLZFQ-PGUFJCEWSA-N 0.000 description 1
- 0 Cc1c2[n]ncc2cc(C[C@](C(N(CC2)CCC2N(CC2)CCC2[Al])=O)NC(N(CC2)CCC2=C(Cc(ccc(*)c2)c2N2)C2=O)=O)c1 Chemical compound Cc1c2[n]ncc2cc(C[C@](C(N(CC2)CCC2N(CC2)CCC2[Al])=O)NC(N(CC2)CCC2=C(Cc(ccc(*)c2)c2N2)C2=O)=O)c1 0.000 description 1
Claims (15)
- Ar1は、少なくとも2つの窒素原子を含む、置換されていてもよい5員の複素環であり、この任意の置換基は、(C1-C6)アルキル、CO2R2から選択され、前記R2はH又は(C1-C3)アルキルである、請求項1に記載の化合物。
- R1がHである、請求項1又は2に記載の化合物。
- Ar1が、2つ又は3つの窒素原子を含む5員の複素環であり、任意で(C1-C6)アルキルで置換されている、請求項1〜3のいずれか1項に記載の化合物。
- 前記化合物が、以下からなる群より選択される、請求項1〜7のいずれか1項に記載の化合物:
N-[(2R)-1-[4-(1H-イミダゾール-2-イル)-1,4'-ビピペリジン-1'-イル]-3-(7-メチル-1H-インダゾール-5-イル)-1-オキソプロパン-2-イル]-4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-カルボキサミド;
N-[(2R)-1-[4-(4-メチル-1H-イミダゾール-5-イル)-1,4'-ビピペリジン-1'-イル]-3-(7-メチル-1H-インダゾール-5-イル)-1-オキソプロパン-2-イル]-4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-カルボキサミド;
N-{(2R)-3-(7-メチル-1H-インダゾール-5-イル)-1-オキソ-1-[4-(1-プロピル-1H-イミダゾール-2-イル)-1,4'-ビピペリジン-1'-イル]プロパン-2-イル}-4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-カルボキサミド;
N-{(2R)-3-(7-メチル-1H-インダゾール-5-イル)-1-[4-(4-メチル-4H-1,2,4-トリアゾール-3-イル)-1,4'-ビピペリジン-1'-イル]-1-オキソプロパン-2-イル}-4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-カルボキサミド;
4-(7-フルオロ-2-オキソ-1,2-ジヒドロキノリン-3-イル)-N-{(2R)-3-(7-メチル-1H-インダゾール-5-イル)-1-[4-(4-メチル-4H-1,2,4-トリアゾール-3-イル)-1,4'-ビピペリジン-1'-イル]-1-オキソプロパン-2-イル}ピペリジン-1-カルボキサミド;
エチル 5-{1'-[(2R)-3-(7-メチル-1H-インダゾール-5-イル)-2-({[4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-イル]カルボニル}アミノ)プロパノイル]-1,4'-ビピペリジン-4-イル}-4H-1,2,4-トリアゾール-3-カルボキシレート;
N-{(2R)-3-(7-メチル-1H-インダゾール-5-イル)-1-オキソ-1-[4-(4H-1,2,4-トリアゾール-3-イル)-1,4'-ビピペリジン-1'-イル]プロパン-2-イル}-4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-カルボキサミド;
N-{(2R)-3-(7-メチル-1H-インダゾール-5-イル)-1-[4-(5-メチル-4H-1,2,4-トリアゾール-3-イル)-1,4'-ビピペリジン-1'-イル]-1-オキソプロパン-2-イル}-4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-カルボキサミド;及び
5-{1'-[(2R)-3-(7-メチル-1H-インダゾール-5-イル)-2-({[4-(2-オキソ-1,2-ジヒドロキノリン-3-イル)ピペリジン-1-イル]カルボニル}アミノ)プロパノイル]-1,4'-ビピペリジン-4-イル}-4H-1,2,4-トリアゾール-3-カルボン酸。 - 非経口投与経路によって投与される組成物であって、請求項1〜9のいずれか1項に記載の化合物を含む組成物。
- 非経口投与経路が、鼻腔内経路、皮下経路、又は静脈内経路である、請求項10に記載の組成物。
- 請求項1〜9のいずれか1項に記載の化合物を含む組成物であって、前兆を伴わない片頭痛、慢性片頭痛、純粋な月経性片頭痛、月経に関連する片頭痛、前兆を伴う片頭痛、家族性片麻痺性片頭痛、孤発性片麻痺性片頭痛、脳底型片頭痛、周期性嘔吐、腹性片頭痛、小児期の良性発作性めまい、網膜性片頭痛、片頭痛発作重積、群発性頭痛、透析性頭痛、発作性片頭痛、変形性関節症、閉経又は手術や薬物治療に起因して医学的に誘発された閉経に関連するホットフラッシュ、持続性片側頭痛、周期性嘔吐症候群、アレルギー性鼻炎、又は酒さ、歯痛、耳痛、中耳炎、日焼け、 変形性関節症及び関節リウマチに関連する関節痛、癌性疼痛、線維筋痛、糖尿病性神経障害、炎症性腸疾患−クローン病に関連する疼痛、痛風、複合性局所疼痛症候群、ベーチェット病、子宮内膜症痛、背部痛又は咳を含む脳血管性疾患又は血管性疾患を治療するための組成物。
- 非経口経路を経て投与される、請求項12に記載の組成物。
- 非経口投与経路が、鼻腔内経路、皮下経路、又は静脈内経路である、請求項13に記載の組成物。
- 請求項1〜9のいずれか1項に記載の化合物を合成する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1519194.3A GB201519194D0 (en) | 2015-10-30 | 2015-10-30 | CGRP receptor antagonists |
GB1519194.3 | 2015-10-30 | ||
PCT/IB2016/056519 WO2017072723A1 (en) | 2015-10-30 | 2016-10-28 | Cgrp receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018532790A JP2018532790A (ja) | 2018-11-08 |
JP2018532790A5 true JP2018532790A5 (ja) | 2019-12-05 |
JP6874014B2 JP6874014B2 (ja) | 2021-05-19 |
Family
ID=55130446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018541593A Active JP6874014B2 (ja) | 2015-10-30 | 2016-10-28 | Cgrp受容体アンタゴニスト |
Country Status (13)
Country | Link |
---|---|
US (3) | US9688660B2 (ja) |
EP (1) | EP3368526B1 (ja) |
JP (1) | JP6874014B2 (ja) |
CN (1) | CN108430991B (ja) |
AR (1) | AR106487A1 (ja) |
AU (1) | AU2016344689A1 (ja) |
BR (1) | BR112018008416A2 (ja) |
CA (1) | CA3002625A1 (ja) |
GB (1) | GB201519194D0 (ja) |
IL (1) | IL258894A (ja) |
SG (1) | SG11201803382XA (ja) |
TW (1) | TW201722936A (ja) |
WO (1) | WO2017072723A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
US20220401439A1 (en) * | 2019-12-17 | 2022-12-22 | Biohaven Pharmaceutical Holding Company Ltd. | Intranasal pharmaceutical compositions of cgrp inhibitors |
WO2024046223A1 (zh) * | 2022-08-30 | 2024-03-07 | 熙源安健医药(上海)有限公司 | 吲唑甲酰胺类衍生物及其制备方法和用途 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2732221B1 (fr) | 1995-03-28 | 1997-04-25 | Oreal | Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue |
NZ334543A (en) | 1996-09-10 | 2000-06-23 | Thomae Gmbh Dr K | Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays |
US20030069231A1 (en) | 1999-10-12 | 2003-04-10 | Klaus Rudolf | Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
AU742425B2 (en) | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
DE19952146A1 (de) * | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
MXPA04011960A (es) * | 2002-06-05 | 2005-03-31 | Squibb Bristol Myers Co | Antagonistas de receptores de peptidos relacionados con el gen de calcitonina. |
JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
US7569578B2 (en) | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
JP2007524568A (ja) | 2003-12-05 | 2007-08-30 | ブリストル−マイヤーズ スクイブ カンパニー | カルシトニン遺伝子関連ペプチドレセプターアンタゴニスト |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
DE102004015723A1 (de) | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US20050233980A1 (en) * | 2004-04-20 | 2005-10-20 | Boehringer Ingelheim International Gmbh | CGRP-antagonist in combination with a serotonin-reuptake inhibitor for the treatment of migraine |
DE102004019492A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
CA2583536A1 (en) | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
CN101039718A (zh) | 2004-10-14 | 2007-09-19 | 默克公司 | Cgrp受体拮抗剂 |
US7745427B2 (en) | 2004-10-22 | 2010-06-29 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
EP1770091A1 (de) | 2005-09-29 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
CA2654048A1 (en) | 2006-06-08 | 2007-12-13 | Boehringer Ingelheim International Gmbh | Treatment of gastrointestinal disorders with cgrp antagonists |
US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
KR101754698B1 (ko) * | 2008-12-19 | 2017-07-26 | 센트렉시온 테라퓨틱스 코포레이션 | 염증, 천식 및 copd 치료용 ccr2 수용체 길항제로서의 사이클릭 피리미딘-4-카복스아미드 |
US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8481546B2 (en) * | 2010-03-30 | 2013-07-09 | Bristol-Myers Squibb Company | CGRP receptor antagonist |
US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
GB201519194D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
-
2015
- 2015-10-30 GB GBGB1519194.3A patent/GB201519194D0/en not_active Ceased
-
2016
- 2016-10-28 WO PCT/IB2016/056519 patent/WO2017072723A1/en active Application Filing
- 2016-10-28 CN CN201680063940.2A patent/CN108430991B/zh active Active
- 2016-10-28 SG SG11201803382XA patent/SG11201803382XA/en unknown
- 2016-10-28 BR BR112018008416A patent/BR112018008416A2/pt not_active Application Discontinuation
- 2016-10-28 US US15/336,893 patent/US9688660B2/en active Active
- 2016-10-28 JP JP2018541593A patent/JP6874014B2/ja active Active
- 2016-10-28 TW TW105135025A patent/TW201722936A/zh unknown
- 2016-10-28 EP EP16808804.5A patent/EP3368526B1/en active Active
- 2016-10-28 AU AU2016344689A patent/AU2016344689A1/en not_active Abandoned
- 2016-10-28 AR ARP160103294A patent/AR106487A1/es unknown
- 2016-10-28 CA CA3002625A patent/CA3002625A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/588,051 patent/US9925178B2/en active Active
-
2018
- 2018-01-29 US US15/882,038 patent/US10166226B2/en active Active
- 2018-04-24 IL IL258894A patent/IL258894A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018532790A5 (ja) | ||
ES2395114T3 (es) | Derivados de triazinona y de diazinona útiles como inhibidores de Hsp90 | |
ES2484042T3 (es) | Compuestos de triazol que modulan la actividad de HSP90 | |
CN101679319B (zh) | 用于治疗增生性病症如癌症的三唑类化合物 | |
ES2415234T3 (es) | Compuestos de triazol que modulan la actividad Hsp90 | |
JP6506779B2 (ja) | 医薬化合物 | |
JP2016516043A5 (ja) | ||
TW201011003A (en) | Triazole compounds that modulate HSP90 activity | |
CN105008350B (zh) | 抗病毒化合物 | |
JP2017528487A5 (ja) | ||
JP2008526723A5 (ja) | ||
JP2018532788A5 (ja) | ||
ES2576497T3 (es) | Compuesto de piperidina novedoso o sal del mismo | |
TW200808746A (en) | Triazole compounds that modulate HSP90 activity | |
JP2015515469A (ja) | Hsp90阻害剤としてのトリアゾール誘導体 | |
JP2016530213A5 (ja) | ||
WO2019025440A1 (en) | COMBINATION OF ATR KINASE INHIBITORS AND PD-1 / PD-L1 INHIBITORS | |
ES2962986T3 (es) | Agentes antifúngicos derivados de piridina sustituida con heterociclo | |
RU2015104962A (ru) | Ди- и тригетероарильные производные в качестве ингибиторов агрегации белков | |
JP2016525104A5 (ja) | ||
JP2018532789A5 (ja) | ||
JP2020535172A5 (ja) | ||
JP2012519668A5 (ja) | ||
JP2017537056A5 (ja) | ||
TW200950782A (en) | Therapeutic agent for cerebral infarction |